Adcetris (brentuximab vedotin) is an antibody conjugated drug (a combination of three components) indicated for treatment of patients with Hodgkin lymphoma (Hodgkin’s disease) and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL). Adcetris is to be used in patients who have received two prior chemotherapy treatments and cannot receive a transplant. Adcetris may also be used in patients with ALCL whose disease has progressed after one prior chemotherapy treatment.Adcetris is available in single–use vials when reconstituted with 10.5 ml of sterile water contain strength of 5 mg per ml brentuximab vedotin.